Association between Ranibizumab Injections and Risk of Acute Myocardial Infarction in Age-related Macular Degeneration: A Case-crossover Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the risk of acute myocardial infarction (AMI) associated with intravitrealranibizumab in age-related macular degeneration (AMD). Methods: This nationwide retrospective case-crossover study using data from the Korean National Health InsuranceService database included patients diagnosed with exudative AMD using the registration code forexudative AMD (V201) from 2009 to 2014. We identified all incident AMI cases among these exudative AMDcases from inpatient claims and defined the index date as the date of hospitalization. For each patient, wedefined the case period as one to 60 days and four control periods as 121 to 180, 181 to 240, 241 to 300, and301 to 361 days, respectively, before the index date. A prescription of ranibizumab was searched for duringthe case and control periods. We calculated the adjusted odds ratios and their 95% confidence intervals usinga conditional logistic regression model. Results: From a cohort of patients with exudative AMD (n = 41,860), a total of 181 AMI patients with exudativeAMD were included. Among all the patients, 11.05% were treated during the 2 months preceding the indexdate as compared with 8.29% to 9.39% treated during control periods. The adjusted odds ratio of AMI associatedwith intravitreal ranibizumab during the preceding 2 months was 1.22 (95% confidence interval, 0.673–2.213; p = 0.5124). Analyses based on case periods of 15 days and 1 month yielded similar results. Conclusions: Intravitreal ranibizumab injection does not appear to increase the risk of hospitalization for AMIwithin 60 days in exudative AMD patients.
Abstract
Purpose: This study aimed to evaluate the risk of acute myocardial infarction (AMI) associated with intravitrealranibizumab in age-related macular degeneration (AMD). Methods: This nationwide retrospective case-crossover study using data from the Korean National Health InsuranceService database included patients diagnosed with exudative AMD using the registration code forexudative AMD (V201) from 2009 to 2014. We identified all incident AMI cases among these exudative AMDcases from inpatient claims and defined the index date as the date of hospitalization. For each patient, wedefined the case period as one to 60 days and four control periods as 121 to 180, 181 to 240, 241 to 300, and301 to 361 days, respectively, before the index date. A prescription of ranibizumab was searched for duringthe case and control periods. We calculated the adjusted odds ratios and their 95% confidence intervals usinga conditional logistic regression model. Results: From a cohort of patients with exudative AMD (n = 41,860), a total of 181 AMI patients with exudativeAMD were included. Among all the patients, 11.05% were treated during the 2 months preceding the indexdate as compared with 8.29% to 9.39% treated during control periods. The adjusted odds ratio of AMI associatedwith intravitreal ranibizumab during the preceding 2 months was 1.22 (95% confidence interval, 0.673–2.213; p = 0.5124). Analyses based on case periods of 15 days and 1 month yielded similar results. Conclusions: Intravitreal ranibizumab injection does not appear to increase the risk of hospitalization for AMIwithin 60 days in exudative AMD patients.
참고문헌 (26)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Frank RN, "Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes", Am J Ophthalmol, 122, pp.393~403 (1996)
- Kvanta A, "Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor", Invest Ophthalmol Vis Sci, 37, pp.1929~1934 (1996)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Simons M, "Angiogenesis : where do we stand now", Circulation, 111, pp.1556~1566 (2005)
- Ferrara N, "The biology of vascular endothelial growth factor", Endocr Rev, 18, pp.4~25 (1997)
- Henry TD, "The VIVA trial : Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis", Circulation, 107, pp.1359~1365 (2003)
- Juan-Babot JO, "Neovascularization in human coronary arteries with lesions of different severity", Rev Esp Cardiol, 56, pp.978~986 (2003)
- Tunon J, "Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration", Surv Ophthalmol, 54, pp.339~348 (2009)
- Kemp A, "Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors : a whole population study", Retina, 33, pp.920~927 (2013)
- Schlenker MB, "Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism", Am J Ophthalmol, 160, pp.569~580 (2015)
- Brown DM, "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration : Two-year results of the ANCHOR study", Ophthalmology, 116, pp.57~65 (2009)
- Abraham P, "Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2", Am J Ophthalmol, 150, pp.315~324 (2010)
- Antoszyk AN, "Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration(FOCUS) : year 2 results", Am J Ophthalmol, 145, pp.862~874 (2008)
- Wong TY, "Age-related macular degeneration and risk of coronary heart disease : the Atherosclerosis Risk in Communities Study", Ophthalmology, 114, pp.86~91 (2007)
- Wong TY, "Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies", Am J Ophthalmol, 148, pp.327~329 (2009)
- Boyer DS, "A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration", Ophthalmology, 116, pp.1731~1739 (2009)
- Busbee BG, "Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration", Ophthalmology, 120, pp.1046~1056 (2013)
- Schmidt-Erfurth U, "Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration : the EXCITE study", Ophthalmology, 118, pp.831~839 (2011)
- IVAN Study Investigators, "Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration : one-year findings from the IVAN randomized trial", Ophthalmology, 119, pp.1399~1411 (2012)
- Ueta T, "Systemic vascular safety of ranibizumab for age-related macular degeneration : systematic review and meta-analysis of randomized trials", Ophthalmology, 121, pp.2193~2203 (2014)
- Ueta T, "Cerebrovascular accidents in ranibizumab", Ophthalmology, 116, pp.362~ (2009)
- Curtis LH, "Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration", Arch Ophthalmol, 128, pp.1273~1279 (2010)
- Pratt NL, "Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration : a self-controlled case-series analysis", Drug Saf, 37, pp.1021~1027 (2014)
- 김희진, "Validity of the Diagnosis of Acute Myocardial Infarction in Korean National Medical Health Insurance Claims Data: The Korean Heart Study (1)", Korean Circulation Journal, 42(1), pp.10~15 (2012), 대한심장학회
- Park JK, "The accuracy of ICD codes for cerebrovascular diseases in medical insurance claims", Korean J Prev Med, 33, pp.76~82 (2000)